CLINICAL_TRIALS ClinicalTrials.gov record update

An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib With or Without Atezolizumab in Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (NERA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05564416
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.763088+00:00
Published At: 2025-10-21T00:00:00+00:00
Record Updated At: 2025-10-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Bladder Carcinoma", "Bladder Urothelial Carcinoma", "Muscle Invasive Bladder Carcinoma", "Renal Pelvis and Ureter Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-21"
protocolSection.identificationModule.nctId: "NCT05564416"
protocolSection.identificationModule.officialTitle: "An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib With or Without Atezolizumab in Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (NERA)"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.